MUMBAI, India, Nov. 2 -- Intellectual Property India has published a patent application (202617094496 A) filed by Xilio Development, Inc. on August 04, 2026, for Masked Il-2 Cytokines And Methods Of Use Thereof.
Inventors include Eryilmaz, Ertan; Bialucha, Carl Uli; and Tomar, Dheeraj.
The application for the patent was published on October 30, 2026, under issue no. 44/2026.
Abstract: The present invention provides, among other things, a masked cytokine comprising an interleukin 2 (IL-2) polypeptide, a VHH masking moiety, an anti-PD1 targeting moiety, and an engineered Fc domain comprising a tumor-associated protease cleavage site. In such masked cytokine, the IL-2 polypeptide is engineered to be activatable by a protease at a target site, such as in a tumor microenvironment. The VHH masking moiety blocks, occludes, inhibits (e.g., decreases) or otherwise prevents (e g masks) the activity or binding of the cytokine to its cognate receptor or protein. Upon proteolytic cleavage of the cleavage site in the Fc domain, the IL-2 polypeptide becomes activated, which renders it capable of binding to its cognate receptor or protein with increased affinity.
Disclaimer: Curated by HT Syndication.
